vs
ANGIODYNAMICS INC（ANGO）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
ANGIODYNAMICS INC的季度营收约是RE/MAX Holdings, Inc.的1.1倍（$79.4M vs $71.1M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -8.0%，领先10.0%），ANGIODYNAMICS INC同比增速更快（9.0% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $4.2M），过去两年ANGIODYNAMICS INC的营收复合增速更高（2.8% vs -4.7%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
ANGO vs RMAX — 直观对比
营收规模更大
ANGO
是对方的1.1倍
$71.1M
营收增速更快
ANGO
高出10.9%
-1.8%
净利率更高
RMAX
高出10.0%
-8.0%
自由现金流更多
RMAX
多$29.3M
$4.2M
两年增速更快
ANGO
近两年复合增速
-4.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $71.1M |
| 净利润 | $-6.3M | $1.4M |
| 毛利率 | 56.4% | — |
| 营业利润率 | -7.7% | 13.1% |
| 净利率 | -8.0% | 2.0% |
| 营收同比 | 9.0% | -1.8% |
| 净利润同比 | 40.9% | -75.2% |
| 每股收益（稀释后） | $-0.15 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGORMAX
| Q4 25 | $79.4M | $71.1M | ||
| Q3 25 | $75.7M | $73.2M | ||
| Q2 25 | $80.2M | $72.8M | ||
| Q1 25 | $72.0M | $74.5M | ||
| Q4 24 | $72.8M | $72.5M | ||
| Q3 24 | $67.5M | $78.5M | ||
| Q2 24 | $71.0M | $78.5M | ||
| Q1 24 | $75.2M | $78.3M |
净利润ANGORMAX
| Q4 25 | $-6.3M | $1.4M | ||
| Q3 25 | $-10.9M | $4.0M | ||
| Q2 25 | $-6.0M | $4.7M | ||
| Q1 25 | $-4.4M | $-2.0M | ||
| Q4 24 | $-10.7M | $5.8M | ||
| Q3 24 | $-12.8M | $966.0K | ||
| Q2 24 | $-13.4M | $3.7M | ||
| Q1 24 | $-187.7M | $-3.4M |
毛利率ANGORMAX
| Q4 25 | 56.4% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 52.7% | — | ||
| Q1 25 | 54.0% | — | ||
| Q4 24 | 54.8% | — | ||
| Q3 24 | 54.4% | — | ||
| Q2 24 | 54.3% | — | ||
| Q1 24 | 47.7% | — |
营业利润率ANGORMAX
| Q4 25 | -7.7% | 13.1% | ||
| Q3 25 | -14.1% | 25.0% | ||
| Q2 25 | -7.2% | 19.3% | ||
| Q1 25 | -13.9% | 7.2% | ||
| Q4 24 | -15.2% | 5.9% | ||
| Q3 24 | -19.4% | 19.4% | ||
| Q2 24 | -20.4% | 20.6% | ||
| Q1 24 | -265.9% | 5.8% |
净利率ANGORMAX
| Q4 25 | -8.0% | 2.0% | ||
| Q3 25 | -14.4% | 5.4% | ||
| Q2 25 | -7.5% | 6.4% | ||
| Q1 25 | -6.1% | -2.6% | ||
| Q4 24 | -14.7% | 8.0% | ||
| Q3 24 | -19.0% | 1.2% | ||
| Q2 24 | -18.9% | 4.7% | ||
| Q1 24 | -249.7% | -4.3% |
每股收益（稀释后）ANGORMAX
| Q4 25 | $-0.15 | — | ||
| Q3 25 | $-0.26 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.11 | — | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.35 | — | ||
| Q1 24 | $-4.67 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $176.3M | $452.4M |
| 总资产 | $269.7M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ANGORMAX
| Q4 25 | $41.6M | $118.7M | ||
| Q3 25 | $38.8M | $107.5M | ||
| Q2 25 | $55.9M | $94.3M | ||
| Q1 25 | $44.8M | $89.1M | ||
| Q4 24 | $54.1M | $96.6M | ||
| Q3 24 | $55.0M | $83.8M | ||
| Q2 24 | $76.1M | $66.1M | ||
| Q1 24 | $78.5M | $82.1M |
总债务ANGORMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | $0 | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益ANGORMAX
| Q4 25 | $176.3M | $452.4M | ||
| Q3 25 | $178.9M | $448.1M | ||
| Q2 25 | $183.0M | $442.4M | ||
| Q1 25 | $185.9M | $433.5M | ||
| Q4 24 | $186.8M | $429.5M | ||
| Q3 24 | $196.6M | $423.1M | ||
| Q2 24 | $205.6M | $418.4M | ||
| Q1 24 | $218.7M | $412.0M |
总资产ANGORMAX
| Q4 25 | $269.7M | $582.5M | ||
| Q3 25 | $265.6M | $582.2M | ||
| Q2 25 | $280.1M | $574.8M | ||
| Q1 25 | $285.4M | $571.4M | ||
| Q4 24 | $291.6M | $581.6M | ||
| Q3 24 | $293.6M | $578.6M | ||
| Q2 24 | $317.7M | $571.4M | ||
| Q1 24 | $324.8M | $566.7M |
负债/权益比ANGORMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | 0.00× | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $33.5M |
| 自由现金流率自由现金流/营收 | 5.3% | 47.1% |
| 资本支出强度资本支出/营收 | 0.5% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $56.8M |
8季度趋势，按日历期对齐
经营现金流ANGORMAX
| Q4 25 | $4.7M | $40.9M | ||
| Q3 25 | $-15.9M | $17.7M | ||
| Q2 25 | $18.8M | $4.6M | ||
| Q1 25 | $-13.2M | $5.7M | ||
| Q4 24 | $2.5M | $59.7M | ||
| Q3 24 | $-18.3M | $17.6M | ||
| Q2 24 | $5.0M | $15.9M | ||
| Q1 24 | $-12.5M | $9.4M |
自由现金流ANGORMAX
| Q4 25 | $4.2M | $33.5M | ||
| Q3 25 | $-16.6M | $16.4M | ||
| Q2 25 | $18.0M | $2.9M | ||
| Q1 25 | $-15.0M | $4.0M | ||
| Q4 24 | $1.7M | $53.0M | ||
| Q3 24 | $-19.3M | $16.3M | ||
| Q2 24 | $4.4M | $14.0M | ||
| Q1 24 | $-13.1M | $6.8M |
自由现金流率ANGORMAX
| Q4 25 | 5.3% | 47.1% | ||
| Q3 25 | -22.0% | 22.4% | ||
| Q2 25 | 22.5% | 4.0% | ||
| Q1 25 | -20.8% | 5.3% | ||
| Q4 24 | 2.3% | 73.2% | ||
| Q3 24 | -28.7% | 20.8% | ||
| Q2 24 | 6.2% | 17.8% | ||
| Q1 24 | -17.5% | 8.6% |
资本支出强度ANGORMAX
| Q4 25 | 0.5% | 10.4% | ||
| Q3 25 | 1.0% | 1.8% | ||
| Q2 25 | 1.0% | 2.2% | ||
| Q1 25 | 2.5% | 2.3% | ||
| Q4 24 | 1.1% | 9.1% | ||
| Q3 24 | 1.6% | 1.7% | ||
| Q2 24 | 0.8% | 2.4% | ||
| Q1 24 | 0.8% | 3.3% |
现金转化率ANGORMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
